- Report
- May 2024
- 184 Pages
Global
From €4295EUR$4,500USD£3,598GBP
- Report
- February 2025
- 200 Pages
Global
From €4285EUR$4,490USD£3,590GBP
- Report
- December 2023
- 155 Pages
Global
From €2362EUR$2,475USD£1,979GBP
€4724EUR$4,950USD£3,958GBP
- Report
- May 2023
- 150 Pages
Global
From €4629EUR$4,850USD£3,878GBP
- Report
- February 2024
- 147 Pages
Global
From €4533EUR$4,750USD£3,798GBP
- Report
- April 2023
- 117 Pages
Global
From €4533EUR$4,750USD£3,798GBP
- Report
- January 2025
- 132 Pages
Global
From €907EUR$950USD£760GBP
- Book
- January 2016
- 472 Pages
In biotechnology, the biologics drug discovery market comprises a specialized sector focused on developing therapeutic drugs derived from biological sources. Unlike traditional pharmaceuticals, which are synthesized chemically, biologics are typically produced using living organisms, including cells and tissues. These complex molecules, such as monoclonal antibodies, recombinant proteins, vaccines, and gene therapies, target various medical conditions with high specificity and potency. The market involves diverse methodologies for drug discovery, including hybridoma technologies for antibody production, advanced genetic engineering for protein design, and high-throughput screening to identify potential drug candidates. The biologics market faces unique challenges, such as intricate manufacturing processes and stringent regulatory requirements, due to the biological nature of these products. However, advancements in biotechnological research and development are leading to the discovery of novel biologics and the optimization of existing therapeutic modalities.
Prominent companies in the biologics drug discovery market include Amgen, Biogen, Roche Genentech, AbbVie, Sanofi, GlaxoSmithKline, Novo Nordisk, and Regeneron Pharmaceuticals. These companies are known for their extensive research and development efforts and have a strong presence in the therapeutics landscape due to their innovative biologics portfolios. Show Less Read more